San Francisco, 05 March, Viral Vector & Plasmid DNA Manufacturing
Market Analysis Report By Application, By Disease (Cancer, Genetic), By
Workflow (Upstream, Downstream), By Vector, By End Use, And Segment Forecasts,
2019 - 2025
The global viralvector & plasmid DNA manufacturing market size is expected
to reach USD 882.9 million by 2025, according to a new report by Grand View
Research, Inc., rising at a 16.0% CAGR during the forecast period. Rising
number of gene therapy-based discovery programs in the pharma industry is one
of the key trends driving the production of gene therapy vectors. Moreover, a
robust pipeline of viral vaccines and gene therapies has prompted companies to
develop novel and effective technologies for scalable manufacturing of vectors.
Current vector manufacturing process is considered highly regulated, elaborate,
and expensive.
Moreover, at present, there is
a shortage of production sites to meet the demand by the pharmaceutical
industry for vector construction services. These factors have created
opportunities for companies to capitalize on potential avenues in the market
through developing novel solutions.
Key growth strategies adopted
by companies to sustain their market presence include continuous expansion of
manufacturing sites in high-demand markets such as the U.S. and U.K. Moreover,
companies are engaged in strategic mergers & facility acquisitions to meet
growing requirements of viral vectors within the pharmaceutical and biotech
industries and to broaden their service portfolios.
Access Full Research
Report On Viral Vector & Plasmid DNA Manufacturing Market Analysis:
Further Key Findings From the Report Suggest:
·
Adenovirus and retrovirus were
prominent vector type segments in the market in 2017. These can be produced at
high titers and induce a strong humoral and, especially, a strong T cell
response, as a result of which these vector type is extensively employed in
vaccines
·
Lentiviral production costs
nearly up to 40.0% of the total cost of goods, thus inducing revenue growth in
this vector type
·
Downstream processing accounted
for the largest share in 2017, owing to requirement of expensive equipment and
skilled personnel for product recovery
·
In terms of application, vector
manufacturing for antisense, RNAi, & molecular therapy production
represented the leading revenue share in 2017. This is due to high adoption
rate of viruses for oligonucleotide and aptamers development in comparison to
other applications
·
The number of biotech companies
that are engaged in employing vector for therapeutic production continue to
increase over the period
·
Recent approval of cancer gene
therapy products encourages further efforts in this arena, thus resulting in
the cancer segment holding the dominant revenue share
·
North America led the global
market owing to presence of several universities and research institutes that
are engaged in genomic research programs
·
Cobra Biologics, Merck, uniQure
N.V., and Novasep are some key participants that are focusing towards
capitalizing of untapped avenues in the market.
Browse More Reports Of This Category By
Grand View Research At: https://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the
global viral vector & plasmid DNA manufacturing market on the basis of
vector type, workflow, application, end-use, disease, and region:
Viral Vector & Plasmid DNA
Manufacturing Vector Type Outlook (Revenue, USD Million, 2014 - 2025)
·
Adenovirus
·
Retrovirus
·
Plasmid DNA
·
AAV
·
Lentivirus
·
Others
Viral Vector & Plasmid DNA
Manufacturing Workflow Outlook (Revenue, USD Million, 2014 - 2025)
·
Upstream Processing
o
Vector Amplification &
Expansion
o
Vector Recovery/Harvesting
·
Downstream Processing
o
Purification
o
Fill-finish
Viral Vector & Plasmid DNA
Manufacturing Application Outlook (Revenue, USD Million, 2014 - 2025)
·
Antisense, RNAi, &
Molecular Therapy
·
Vaccinology
Viral Vector & Plasmid DNA
Manufacturing End-use Outlook (Revenue, USD Million, 2014 - 2025)
·
Pharmaceutical and
Biopharmaceutical Companies
·
Research Institutes
Viral Vector & Plasmid DNA
Manufacturing Disease Outlook (Revenue, USD Million, 2014 - 2025)
·
Cancer
·
Genetic Disorders
·
Infectious Diseases
·
Others
Viral Vector & Plasmid DNA
Manufacturing Regional Outlook (Revenue, USD Million, 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
U.K.
·
Asia Pacific
o
China
o
Japan
·
Latin America
o
Brazil
·
Middle East & Africa
o
South Africa
Browse Press
Release of this Report:
www.grandviewresearch.com/press-release/global-viral-vector-plasmid-dna-manufacturing-market
www.grandviewresearch.com/press-release/global-viral-vector-plasmid-dna-manufacturing-market
About Grand View
Research
Grand View
Research provides syndicated as well as customized research reports and
consulting services on 46 industries across 25 major countries worldwide. This
U.S.-based market research and consulting company is registered in California
and headquartered in San Francisco. Comprising over 425 analysts and
consultants, the company adds 1200+ market research reports to its extensive
database each year. Supported by an interactive market intelligence platform,
the team at Grand View Research guides Fortune 500 companies and prominent
academic institutes in comprehending the global and regional business
environment and carefully identifying future opportunities.
For more
information: www.grandviewresearch.com/
No comments:
Post a Comment